id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2204-0007,FDA,FDA-2020-E-2204,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-08-29T04:00:00Z,2022,8,2022-08-29T04:00:00Z,,2022-08-29T17:19:58Z,,0,0,0900006485287604
FDA-2020-E-2204-0006,FDA,FDA-2020-E-2204,Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI,Notice,Determinations,2021-11-09T05:00:00Z,2021,11,2021-11-09T05:00:00Z,2022-01-11T04:59:59Z,2021-11-09T14:57:45Z,2021-24435,0,0,0900006484e37d4d
FDA-2020-E-2204-0005,FDA,FDA-2020-E-2204,Patent Term Extension letter from FDA CDER to The Honorable Drew Hirshfield,Other,Letter(s),2021-11-05T04:00:00Z,2021,11,2021-11-05T04:00:00Z,,2021-11-05T14:59:13Z,,0,0,0900006484e25926
FDA-2020-E-2204-0004,FDA,FDA-2020-E-2204,Patent Term Extension Letter from US Patent and Trademark Office,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T17:09:26Z,,0,0,0900006484c0f06c
FDA-2020-E-2204-0003,FDA,FDA-2020-E-2204,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T20:13:06Z,,0,0,090000648499d78a
FDA-2020-E-2204-0001,FDA,FDA-2020-E-2204,Letter from US Patent and Trademark Office,Other,Letter(s),2020-11-16T05:00:00Z,2020,11,2020-11-16T05:00:00Z,,2020-11-16T21:15:09Z,,0,0,0900006484962542
FDA-2020-E-2204-0002,FDA,FDA-2020-E-2204,"Patent Term Extension Application from Ultragenyx  Pharmaceutical, Inc.",Other,Application,2020-11-16T05:00:00Z,2020,11,2020-11-16T05:00:00Z,,2020-11-16T21:17:42Z,,0,0,0900006484962543